• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 29, 2019

View Archived Issues

'Value' replacing R&D as justification for high-priced U.S. prescription drugs

For years, the biopharma industry has justified U.S. prescription drug prices by pointing to the high cost of years-long R&D and the too-real risk of failure. But in the current paradigm, a hefty launch price, more often than not, seems to reflect the cost of acquisition and is couched in terms of "value." That point was driven home last week when Novartis AG announced that its newly approved gene therapy, Zolgensma (onasemnogene abeparvovec), would list at $2.1 million.  Read More

Evenamide glitch a minor hitch? Newron shares slip

DUBLIN – Shares in Newron Pharmaceuticals SpA dropped by as much as 20.5% Tuesday on news that preclinical toxicity findings would delay the start of pivotal trials of its candidate schizophrenia treatment evenamide by at least six months. Read More

Biomarin sees durability in hemophilia A gene therapy, gives phase III data peek

New data on Biomarin Pharmaceutical Inc.'s investigational treatment for severe hemophilia A, valoctocogene roxaparvovec (valrox), sparked mild debate among analysts who expressed appreciation for the gene therapy's apparent durability but uncertainty regarding interim data from a phase III test of the medicine. But overall, it "at least met – and in some cases exceeded – the majority of investors' expectations," J.P. Morgan analyst Cory Kasimov said. Though the market rendered its own verdict, driving company shares (NASDAQ:BMRN) 5.1% lower to $84.50 by Tuesday's close, the program seemed poised to retain significant interest going forward. Read More

Lilly fills its non-opioid void through deal with Centrexion

Eli Lilly and Co. acquired worldwide rights for CNTX-0290, a somatostatin receptor type 4 agonist as a non-opioid treatment for chronic pain, from Centrexion Therapeutics Corp. Read More

Korean regulator set to boost staff, shorten time to market for new drug applications

HONG KONG – To get new drugs to the market faster, the South Korean government has plans that could see approval periods for biopharmaceuticals cut drastically, as part of its ongoing efforts to improve regulations and prompt greater investing in the biotechnology and health care industries, increasingly seen as a key pillar of economic growth. Read More

Oxford Biomedica bags $68M as Novo buys in to dual strategy

DUBLIN – Oxford Biomedica plc is banking £53.5 million (US$67.7 million) from a strategic investment by Novo Holdings A/S, under which the latter firm will acquire a 10.1% stake in the gene therapy firm. Read More

Looking between the lines leads to neurofibromatosis insight

Characterized by large numbers of benign but highly disfiguring tumors, neurofibromatosis 1 (NF-1) is anything but a subtle disease. Because they are glaringly conspicuous, research into NF-1 has largely focused on the tumors themselves. But in the May 20, 2019, issue of PLoS ONE, researchers have reported new insights into the disease that stem from looking not at the tumors themselves but at tumor-free skin from NF-1 patients. Read More

Shionogi plans Italy, Poland sales of Rizmoic from 2020

HONG KONG – Seeking to expand its presence in Europe, Shionogi & Co. Ltd. inked a contract with Italian firm Molteni Farmaceutici SpA to distribute Rizmoic (naldemedine), its treatment for opioid-induced constipation (OIC), in Italy and Poland, and plans to export two additional drugs, cefiderocol and lusutrombopag, to the European market. Read More

Financings

Prevail Therapeutics Inc., of New York, filed to raise up to $100 million in an IPO. The gene therapy company plans to list on Nasdaq under the symbol PRVL. Morgan Stanley, Bofa Merrill Lynch and Cowen serve as joint bookrunners. Read More

Regulatory front

Teva Pharmaceuticals Co. Ltd., of Jerusalem, agreed to an $85 million settlement with Oklahoma two days ahead of a trial on the company's role in fueling the state's opioid epidemic.  Read More

Other news to note

Biomunex Pharmaceuticals SA, of Paris, said it established a U.S. subsidiary, Biomunex Pharmaceuticals Inc., based in Cambridge, Mass. The company's plug-and-play Bixab platform is designed to generate next-generation bi- and multispecific antibodies. Read More

Clinical data for May 28, 2019

Read More

Regulatory actions for May 28, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe